

1 **Title:**

2 Different activation signals induce distinct mast cell degranulation strategies

3

4 Nicolas Gaudenzio^{1,2}, Riccardo Sibilano^{1,2,#}, Thomas Marichal^{3,#}, Philipp Starkl^{1,2}, Laurent L.

5 Reber^{1,2}, Nicolas Cenac⁴, Benjamin D. McNeil⁵, Xinzhong Dong^{5,6}, Joseph D. Hernandez^{1,2},

6 Ronit Sagi-Eisenberg⁷, Ilan Hammel⁸, Axel Roers⁹, Salvatore Valitutti⁴, Mindy Tsai^{1,2}, Eric

7 Espinosa^{4,*} and Stephen J. Galli^{1,2,10,*}.

8

9 ¹ Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA

10 ² Sean N. Parker Center for Allergy Research, Stanford University School of Medicine, CA 94305,
11 USA

12 ³ GIGA-Research and Faculty of Veterinary Medicine, University of Liege, Liege, Belgium

13 ⁴ Institut National de la Santé et de la Recherche Médicale, U1043, Toulouse F-31300, Inserm,
14 U1043, Toulouse, France

15 ⁵ The Solomon H. Snyder Department of Neuroscience, Center for Sensory Biology Johns
16 Hopkins University, School of Medicine, Baltimore, MD 21205

17 ⁶ Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD
18 21205

19 ⁷ Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel-Aviv University,
20 Ramat Aviv, Tel Aviv, Israel 69978

21 ⁸ Department of Pathology, Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv,
22 Tel Aviv, Israel 69978

23 ⁹ Institute for Immunology, University of Technology Dresden, Medical Faculty Carl-Gustav Carus,
24 01307 Dresden, Germany

25 ¹⁰ Department of Microbiology & Immunology Stanford University School of Medicine, Stanford,

26 CA 94305, USA

27 # and * Equal contribution; correspondence should be addressed to:

28

29 Eric Espinosa

30 UMR 1043 INSERM

31 CPTP CHU Purpan

32 BP3028

33 31024 Toulouse, France

34 Telephone: 0562748304

35 Email: eric.espinosa@inserm.fr (E.E.)

36 or

37 Stephen J. Galli

38 269 Campus Drive, Room 3255b

39 Stanford, CA 94305-5176, USA

40 Telephone: (650) 736-6014

41 Email: sgalli@Stanford.edu

42

43

44

45

46

47

48

49

Supplemental Methods

50

51 **Mice.**

52 C57BL/6J (WT) mice were obtained from Jackson Laboratories and either bred at the Stanford
53 University Research Animal Facility or used for experiments after maintaining the mice for at least
54 two weeks in our animal facility. C57BL/6-*Kit^{W-sh/W-sh}* mice were originally provided by Peter
55 Besmer (Molecular Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY,
56 USA); we then backcrossed these mice to C57BL/6J mice for more than 11 generations(1).
57 C57BL/6-*Mcpt5-Cre⁺* mice were provided by Axel Roers (Institute for Immunology, University of
58 Technology Dresden, Medical Faculty Carl-Gustav Carus, Dresden, Germany) and bred at the
59 Stanford University Research Animal Facility. B6.129X1-*Gt(ROSA)26Sor^{tm1(EYFP)Cos/J}* (*R26^{Y+}*)
60 mice were obtained from Jackson Laboratories and bred at the Stanford University Research
61 Animal Facility. C57BL/6-*MrgprB2^{MUT}* and C57BL/6-*MrgprB2^{+/+}* littermate control mice were
62 provided by Xinzhong Dong (The Solomon H. Snyder Department of Neuroscience, Johns
63 Hopkins University, Baltimore, USA) and bred at the Stanford University Research Animal Facility.
64 We used age-matched (8-10 weeks old) female mice for all experiments, except for experiments
65 using *MrgprB2^{MUT}* and littermate controls where both age-matched male and female mice were
66 used.

67

68 **MC stimuli.**

69 Substance P acetate (#S6883), compound 48/80 (#C2313), Endothelin-1 (#E7764), and 2, 4-
70 dinitrophenyl-conjugated human serum albumin (DNP-HSA, #A6661) were all from Sigma
71 Aldrich, USA. Icatiban HOE140 (#22968) and Cetrorelix acetate (#60869) were both from
72 Anaspec, USA. Recombinant human complement component C5a (#2037-C5-025) was from
73 R&D systems, USA, and recombinant human complement component C3a (#204881) was from
74 Calbiochem, USA. Mouse anti-dinitrophenol (DNP) mAb was from Abnova (#MAB3977).

75 ***Immunoprecipitation and Western blot analysis.***

76 3x 10⁶ PBCMCs were used for each condition and tested at various time points. Human IgE-
77 sensitized (2 µg/ml, for 16 hours) or non-sensitized PBCMCs were washed and stimulated with 2
78 µg/ml of anti-IgE or 10 µM SP respectively (**Figures 3, 4**). PBCMC lysates were prepared in 100
79 µl lysis buffer (#89856C, Thermo Scientific) supplemented with protease inhibitors (Roche)
80 according to the manufacturer's instructions. PBCMCs were lysed at resting condition (0 minutes),
81 and at 5 and 15 minutes after addition of stimuli. For Western blot analysis, total protein extracts
82 were resolved onto a polyacrylamide gel, under reducing conditions. Blotted extracts were probed
83 with the indicated antibodies. For immunoprecipitation experiments, lysates were mixed with
84 Dynabeads Protein G Immunoprecipitation Kit resin (#10007D, Life Technologies) and proteins
85 of interest were immunoprecipitated according to the manufacturer's instructions. Elution of the
86 protein complexes was performed under non-reducing conditions. Immunoprecipitated proteins
87 were resolved onto a polyacrylamide gel under reducing conditions, blotted and probed with the
88 indicated antibodies. For verification of the specificity of the antibodies used for
89 immunoprecipitation (**Supplemental Figure 10**), we tested their reactivity with 0.5 µg of the
90 following recombinant proteins (all from Abcam): recombinant Human Syntaxin 3 protein
91 (#ab124597), recombinant Human Syntaxin 4 protein (#ab114464), and recombinant Human
92 SNAP23 protein (#ab79180).

93

94 ***Measurements of lipid mediators.***

95 *Supernatant lipid extraction.*

96 To 500 µl of cell supernatant, we added 5 µl of internal standard (LxA4-d5, at 400 ng/ml, in MeOH)
97 and 300 µl of cold methanol. Samples were centrifuged at 3000 rpm for 15 min at 4°C.
98 Supernatants were collected, brought to a volume of 2 ml in H₂O and submitted to solid-phase
99 extraction using HRX-50 mg 96-well (Macherey Nagel, Hoerd, France) as previously

100 described(2). Solvent was evaporated under nitrogen and samples were dissolved with MeOH
101 and stored at -80 °C for liquid chromatography/tandem mass spectrometry measurements.

102 *Targeted LC-MS/MS-based lipidomics of mast cell supernatants.*

103 To simultaneously separate lipids of interest (PGE₂ and PGD₂) and 1 deuterated internal
104 standards, LC-MS/MS analysis was performed on an ultra-high performance liquid
105 chromatography system (UHPLC, Agilent LC1290 Infinity) coupled to Agilent 6460 triple
106 quadrupole MS (Agilent Technologies) equipped with electro-spray ionization operating in
107 negative mode(2). Reverse-phase UHPLC was performed using a ZorBAX SB-C18 column
108 (Agilent Technologies) with a gradient elution. The mobile phases consisted of water, acetonitrile
109 (ACN) and formic acid (FA) (75:25:0.1;v/v/v) (A) and ACN, FA (100:0.1, v/v) (B). The linear
110 gradient was as follows: 0% B at 0 min, 85% B at 8.5 min, 100% B at 9.5 min, 100% B at 10.5
111 min and 0% B at 12 min. The flow rate was 0.35 ml/min. The autosampler was set at 5°C and the
112 injection volume was 5 µl. Data were acquired in Multiple Reaction Monitoring (MRM) mode with
113 optimized conditions. Peak detection, integration and quantitative analysis were done using Mass
114 Hunter Quantitative analysis software (Agilent Technologies). For each standard, calibration
115 curves were built using 10 solutions at concentration ranging from 0.95 ng/ml to 500 ng/ml. A
116 linear regression with a weight factor of 1/X was applied for each compound. The limit of detection
117 (LOD) and the limit of quantification (LOQ) were determined for the 2 compounds using signal to
118 noise ratio (S/N). The LOD corresponded to the lowest concentration leading to a signal to noise
119 over 3 and LOQ corresponded to the lowest concentration leading to a signal to noise over 10.
120 All values under the LOQ were not considered. Importantly, blank samples were evaluated, and
121 their injection showed no interference (no peak detected), during the analysis.

122

123 ***IgE-dependent systemic anaphylaxis and substance P-induced systemic responses.***

124 *IgE-dependent systemic anaphylaxis.*

125 We used the passive systemic anaphylaxis (PSA) model to induce a systemic IgE-dependent
126 reaction. Mice were sensitized by mean of intraperitoneal injection (i.p.) of 10 µg of mouse DNP-
127 HSA-specific IgE(3, 4) in 200 µl PBS, and control mice were mock-injected i.p. with 200 µl of PBS.
128 16 hours later, sensitized or non-sensitized control mice were injected i.p. with 500 µg of DNP-
129 HSA and rectal temperature was measured at different time points during a period of 120 min.

130 *Substance P-induced systemic reactions.*

131 Mice were injected i.p. with 200 µl of PBS in order to receive a treatment similar to that of the IgE-
132 sensitized mice. 16 hours later, mice were injected i.p. with 1 mg of SP in 200 µl PBS or 200 µl
133 PBS as a control, and rectal temperature was measured at different time points during a period
134 of 120 min.

135 The doses of DNP-HSA and SP we used in these experiments were the doses which, in
136 preliminary experiments, induced the strongest drop in body temperature.

137

138 ***IgE-dependent and substance P-dependent cutaneous inflammation.***

139 The left and right ear pinnae of C57BL/6 wild type mice were sensitized by means of an
140 intradermal (i.d.) injection with mouse DNP-HSA-specific IgE(5) (20 ng in 20 µl PBS) or received
141 an i.d. injection of 20 µl PBS (control), respectively. 16 h later, the left ear pinna was injected i.d.
142 with DNP-HSA (5 ng in 20 µl) to induce IgE-dependent inflammation, while the right ear pinna
143 was injected i.d. with SP (1 nmol in 20 µl) to induce IgE-independent inflammation. Some ear
144 pinnae were injected i.d. with 20 µl of PBS to assess the extent to which the observed
145 inflammation was due to the i.d. injection. Measurement of Evan's blue dye extravasation and ear
146 swelling, and toluidine blue and hematoxylin and eosin staining (H&E) of histological sections of
147 ear pinnae, were performed as previously described(5).

148

149 ***Foot pad challenge and assessment of effects on draining lymph nodes (DLNs).***

150 The left and right foot pads of C57BL/6 wild type mice were sensitized by means of an intradermal
151 (i.d.) injection with mouse DNP-HSA-specific IgE(5) (20 ng in 20 μ l PBS) or 20 μ l PBS (control),
152 respectively. 16 h later, the left foot pad was injected i.d. with DNP-HSA (5 ng in 20 μ l) to induce
153 IgE-dependent inflammation, while the right foot pad was injected i.d. with SP (1 nmol in 20 μ l) to
154 induce IgE-independent inflammation. Some foot pads were injected i.d. with 20 μ l of PBS to
155 assess the extent to which the observed inflammation was due to the i.d. injection. Measurement
156 of Evan's blue dye extravasation and toluidine blue staining of foot pad histological sections were
157 performed as previously described(5). In some experiments, histological sections of DLNs were
158 stained with toluidine blue or Av.SRho 2 hours after challenge to assess whether LN-resident
159 MCs exhibited degranulation and to search for the presence of mast cell granule structures(6).
160 The presence of individual metachromatic granule structures in DLNs was carefully assessed by
161 light microscopy using an X100 oil objective on Toluidine Blue-stained sections, whereas we
162 examined sections of the DLNs for the presence of Av.SRho⁺ mast cell granule structures by
163 immunofluorescence. In other experiments, DLNs were removed and weighed 24 hours after
164 injection of the footpads(6).

165

166 ***Peripheral blood mononuclear cell-derived human mast cells.***

167 Peripheral blood mononuclear cells were obtained from buffy coats of healthy blood donors at the
168 Stanford Blood Center. CD34⁺ precursor cells were isolated from peripheral blood mononuclear
169 cells (EasySep Human CD34 Positive Selection Kit, STEMCELL Technologies). CD34⁺ cells were
170 maintained for 1 week under serum-free conditions using StemSpan medium (STEMCELL
171 Technologies) supplemented with recombinant human IL-6 (50 ng/ml; Peprotech), human IL-3
172 (10 ng/ml; Peprotech) and 3% supernatant of CHO transfectants secreting murine SCF (a gift
173 from Dr P. Dubreuil, Marseille, France, 3% correspond to ~50 ng/ml SCF). Thereafter, the cells

174 were maintained in IMDM Glutamax I, sodium pyruvate, 2-mercaptoethanol, 0.5% BSA, insulin-
175 transferrin selenium (all from Invitrogen), ciprofloxacin (10 µg/ml; Sigma-Aldrich), IL-6 (50 ng/ml)
176 and 3% supernatant of CHO transfectants secreting mouse SCF. Before use in experiments,
177 PBCMCs were tested for phenotype by flow cytometry (tryptase, chymase, CD117, FcεRI) and
178 function (β-hexosaminidase release in response to FcεRI cross-linking) at 8-12 weeks. PBCMCs
179 were usually ready for experiments after ~10 weeks in culture.

180

181 ***Generation and culture of mouse peritoneal cell-derived mast cells (PCMCs).***

182 PCMCs were generated as previously described(7, 8). Briefly, Peritoneal cells from C57BL/6 mice
183 were collected and seeded in Opti-MEM medium supplemented with 10% FCS, 100 IU/mL
184 penicillin, 100 µg/mL streptomycin (Invitrogen), and 3% supernatant of CHO transfectants
185 secreting mouse SCF (a gift from Dr. P. Dubreuil, Marseille, France). 24 hours later, nonadherent
186 cells were removed and fresh culture medium was added to adherent cells. Three days later,
187 nonadherent cells and adherent cells were harvested by flushing and resuspended in fresh culture
188 medium. The same procedure was repeated twice a week. Cells were used for experiments
189 between weeks 4 and 10, when MCs represented >95%% of the cell population(8).

190

191 ***Antibodies.***

192 Rabbit polyclonal IgG anti-phospho IKKα (Ser176)/IKKβ (Ser177) (C84E11), PKC (gamma T514),
193 AKT (T308) and rabbit polyclonal IgG anti-actin antibodies were from Cell Signaling Technology,
194 USA. Rabbit polyclonal IgG anti-SNAP-23 (Ab4114) and anti-Syntaxin 4 (STX-4, Ab101879) and
195 rabbit polyclonal IgG anti-Syntaxin 3 (STX-3, Ab4113) were from Abcam, USA. Rabbit polyclonal
196 IgG anti-Munc 18-2 was from Proteintech, USA. Rat IgG2b-APC isotype control (clone
197 eB149/10H5), Rat IgG2b-FITC isotype control (clone eB149/10H5), Rat IgG2a-PE isotype control
198 (clone r2a-21B2), rat IgG2b anti-mouse CD45-APC (clone 30-F11) and rat IgG2b anti-mouse GR-

199 1-FITC (clone RB6-8C5) were all from eBioscience, USA. Rat IgG2a anti-mouse F4/80-PE (clone
200 BM8) was from Biolegend, USA, human IgE myeloma was from Calbiochem, USA, and rabbit
201 anti-human IgE were from Bethyl Laboratories, USA. Mouse IgG2a anti-human IgE (clone MH25-
202 1) and goat polyclonal IgG anti-human tryptase (G-12) were both from Santa Cruz Biotechnology,
203 USA. Mouse IgG1 anti-DNP (clone B136M) was from Abnova, Taiwan. Mouse IgE anti-DNP clone
204 ε26(9) was initially provided by Dr. Fu-Tong Liu, University of California–Davis, Davis, CA, USA.

205

206 ***MRGPRX2 knock down by shRNA transfection.***

207 *E. coli*-amplified Suresilencing shRNA plasmids from Qiagen were used. PBCMCs were
208 generated as described in the main Methods section. After 10 weeks of culture, 1×10^6 PBCMCs
209 were transfected using the Attractene reagent (Qiagen) with 1.2 μg DNA of *MRGPRX2*
210 Suresilencing shRNA plasmids (Qiagen, Cat# KM59132G) or negative control shRNA plasmids
211 both containing a reporter GFP in 6-well plates, for 48 hours. The degranulation dynamics of GFP-
212 expressing PBCMCs were analyzed by confocal laser-scanning microscopy (as described below).

213

214 ***Measurement of secretion of mast cell mediators and cytokines in vitro.***

215 1×10^5 IgE-sensitized (1 μg/ml for 16 hours) or non-sensitized PBCMCs were plated in 100 μl of
216 IMDM with GlutaMAX-I, sodium pyruvate, 2-mercaptoethanol, 0.5% BSA and 0.5% supernatant
217 of Chinese hamster ovary transfectants secreting mouse stem cell factor. Different concentrations
218 of anti-human IgE or SP were added to IgE-sensitized and non-sensitized PBCMCs, respectively,
219 for different periods of time and the amount of MC degranulation was assessed as % release of
220 total β-hexosaminidase(10) the amounts of lipid mediators release were quantified as described
221 above in ***Measurements of lipid mediators***, and the amounts of secreted cytokines were
222 quantified in the supernatants by cytometric bead array (CBA, BD Bioscience, USA) according to
223 the manufacturer's recommendations.

224 ***IKK β inhibition in MCs.***

225 2×10^6 PBCMCs were incubated for 60 min at 37°C with 100 μ M of BMS-345541 (4[2'-
226 aminoethyl]amino-1,8-dimethylimidazo[1,2-a]quinoxaline, Sigma Aldrich) in dimethyl sulfoxide
227 (DMSO), or with the same volume of DMSO alone, before performing the experiments described
228 in **Figure 4**.

229

230 ***Flow cytometry analyses.***

231 *Mast cell degranulation analysis.*

232 5×10^4 human IgE-sensitized or non-sensitized PBCMCs were plated in 100 μ l of Tyrode's buffer
233 and stimulants were added to the cell culture. 30 to 60 min later, 5 μ g/ml of Alexa488-coupled
234 avidin (Av.A488, #A-21370, Life Technologies, USA) was added together with 1 μ g/ml of
235 propidium iodide (PI, to assess cell viability, #P3566, Life Technologies, USA) and PI⁻ Av.A488⁺
236 PBCMCs were analyzed using an AccuriC6 flow cytometer (BD Bioscience, USA). For time-lapse
237 flow cytometry analyses, 5×10^5 IgE-sensitized or non-sensitized PBCMCs were stimulated as
238 previously described in a final volume of 1 ml Tyrode's buffer supplemented with 5 μ g/ml of
239 Av.A488. Detection of PI⁻ Av.A488⁺ PBCMCs was recorded upon addition of stimulatory
240 molecules using the time-lapse function of an AccuriC6 flow cytometer (BD Bioscience, USA).

241 *Analysis of tissue immune cells.*

242 One cm² ear pinnae sections were cut into small pieces and digested in Dulbecco's Modified
243 Eagle's medium (DMEM) supplemented with 20 mM HEPES, 10 μ g/ml of Collagenase,
244 Hyaluronidase and DNase for 90 min at 37 °C while shaking. Tissue suspensions were then
245 filtered and cells were stained with primary antibodies directed against different immune cells
246 populations (neutrophils, monocytes/macrophages and T lymphocytes). One μ g/ml of PI were

247 added to the cell suspensions and PI⁻ CD45⁺ immune cell populations were analyzed using a flow
248 cytometer AccuriC6 (BD Bioscience).

249

250 ***Transmission Electron Microscopy.***

251 PBCMCs were pelleted and re-suspended in 10% Gelatin in 0.1M Sodium Cacodylate buffer pH
252 = 7.4 at 37°C and allowed to equilibrate for 5 minutes. Cells were pelleted again, excess gelatin
253 was removed, and the cells then were chilled in cold blocks, covered with cold 1% Osmium
254 tetroxide (EMS Cat# 19100), and rotated for 2 hours in a cold room. The fixed specimens then
255 were washed 3X with cold ultrafiltered water, then stained overnight in bloc in 1% Uranyl Acetate
256 at 4°C while rotating. Samples were then dehydrated in a series of ethanol washes for 20 minutes
257 each at 4°C beginning at 30%, 50%, 70%, and 95%, when the samples then were allowed to rise
258 to RT, changed to 100% ethanol 2X, then Propylene Oxide (PO) for 15 min. Samples were
259 infiltrated with EMbed-812 resin (EMS Cat#14120) mixed 1:2, 1:1, and 2:1 with PO for 2 hours
260 each, then samples were left in 2:1 resin:PO overnight rotating at RT in the hood. The samples
261 were then placed into EMbed-812 for 2 to 4 hours, then placed into molds with labels and fresh
262 resin, orientated, and placed into a 65° C oven overnight. Sections were taken at ~ 80nm, picked
263 up on formvar/Carbon-coated 100 mesh Cu grids, stained for 30 seconds in 3.5% Uranyl Acetate
264 in 50% Acetone followed by staining in 0.2% Lead Citrate for 3 minutes. Sections were examined
265 in a JEOL JEM-1400 120kV and photos were taken using a Gatan Orius 4k X 4k digital camera.
266 Images of 30 intact mast cells in photomicrographs from each specimen analyzed were selected
267 randomly (by taking pictures of mast cells in sequence as they appeared in the microscope field),
268 and, for each mast cell, the area of the section of each exteriorized granule structure which
269 appeared to be separated from the cell was analyzed using area function of ImageJ software. For
270 each experimental condition analyzed, 700 to 750 exteriorized granule structures were measured.

271

272 **Confocal laser-scanning microscopy.**

273 *Single cell analysis of mast cell degranulation dynamics.*

274 5×10^4 human IgE-sensitized or non-sensitized PBCMCs were placed into poly-D-Lysine-coated
275 ($5 \mu\text{g/ml}$ in water, #P6407, Sigma Aldrich, USA) Nunc Lab-Tek 1.0 borosilicate cover glass system
276 8 chambers (#155411, ThermoScientific, USA) in Tyrode's buffer supplemented with $5 \mu\text{g/ml}$ of
277 avidine-sulforodamine 101 (Av.SRho, #A2348, Sigma Aldrich, USA), as previously described(11).
278 Stimuli were added and fluorescence was recorded each 2.3 seconds in a controlled atmosphere
279 (using a Zeiss stage-top incubation system with objective heater, 37°C and 5% humidified CO_2)
280 using a Zeiss LSM710 or a Zeiss LSM780 Meta inverted confocal laser-scanning microscope,
281 $20 \times / 0.8 \text{ WD} = 0.55 \text{ M27}$ objective and electronic zoom 1 (8 bits/pixel 512×512) for single cell
282 Av.SRho fluorescence monitoring, and $63 \times / 1.40 \text{ Oil DIC M27}$ objective and electronic zoom 3
283 (dimension x:512 y:512, scaling x= $0.264 \mu\text{m}$ and y= $0.264 \mu\text{m}$) for high resolution single cell
284 analyzes or monitoring of individual granule structures. In some experiments, cells were also
285 loaded with $1 \mu\text{g}$ Fluo-4 AM (#F-14217, Life Technologies, USA) to monitor $[\text{Ca}^{2+}]_i$ levels, and
286 data were presented as fold-increase from Fluo-4 fluorescence measured before addition of any
287 stimulus. Mean fluorescence intensity (MFI) was quantified using the Measurement function of
288 Image J software, on randomly selected fields and untreated image sequences. Modeling and
289 analysis of budding granule structures were performed on untreated image sequences, as
290 described below in the "**Granule modeling and analysis**" section.

291 *Dextran-FITC dequenching assay.*

292 5×10^4 PBCMCs were incubated with 1 mg/ml fluorescein isothiocyanate-dextran (dextran-FITC,
293 #46945, Sigma Aldrich, USA) for 48 hours in previously described culture medium(12). 5×10^4
294 dextran-FITC-loaded human IgE-sensitized or non-sensitized PBCMCs were placed into poly-D-
295 Lysine-coated Nunc Lab-Tek 1.0 borosilicate cover glass system 8 chambers in Tyrode's buffer
296 supplemented with $5 \mu\text{g/ml}$ of Av.SRho, as described above. Stimuli were added and dextran-

297 FITC and Av.SRho fluorescence signals were recorded simultaneously in a controlled
298 atmosphere. To avoid any bleaching of FITC fluorescence due to repeated laser exposures,
299 images were acquired every 10 seconds using a Zeiss LSM780 Meta inverted confocal laser-
300 scanning microscope, 20x/0.8 WD=0.55 M27 objective and electronic zoom 1 (8 bits/pixel
301 256x256). MFI was quantified on randomly selected fields and untreated image sequences using
302 the Measurement function of Image J software. To correct for differences in the loading of dextran-
303 FITC between PBCMCs and experiments, the dextran-FITC fluorescence of each single
304 unstimulated PBCMC was normalized to reach the average of dextran-FITC fluorescence per cell
305 measured over all the experiments.

306 *In vitro 3-D degranulation assay.*

307 5×10^3 Fluo-4-loaded human IgE-sensitized or non-sensitized PBCMCs were embedded in 200 μ l
308 of a 7.8 mg/ml Matrigel Matrix (#354248, Corning, USA) and placed in Nunc Lab-Tek 1.0
309 borosilicate cover glass system 8 chambers in Tyrode's buffer supplemented with 5 μ g/ml of
310 Av.SRho, as described above. 30 min after stimuli addition, z-stack images sequence
311 corresponding to randomly selected single PBCMCs were acquired in 3-D up to 20-30 μ m depth,
312 with 20x/0.8 WD=0.55 M27 objective and electronic zoom 3 (8 bits/pixel 512x512, scaling x=
313 0.277 μ m, y= 0.277 μ m, z= 1.0 μ m). Modeling and analysis of released granule structures were
314 performed on untreated image sequences, as described below in the "**Granule modeling and**
315 **analysis**" section.

316

317 *Two-photon microscopy.*

318 *Single cell analysis of tissue mast cell granule characteristics.*

319 The ear pinnae of C57BL/6-*Mcpt5-Cre*⁺; *R26Y*⁺ mice were sensitized by i.d. injection of 20 ng of
320 mouse anti-DNP IgE(5) in 20 μ l PBS or received an i.d. injection of 20 μ l PBS as a control. 16 h
321 later, 8 μ g of Av.SRho in 20 μ l were injected i.d. into the ear pinna under the two-photon

322 microscope, anesthesia was maintained by a mixture of Isoflurane/O₂ and the animal's ear pinna
323 was kept at 36°C using a heating pad system for 20 min. To induce a SP-mediated systemic
324 anaphylaxis, non-sensitized *Mcpt5-Cre⁺; R26Y⁺* mice received an i.p. injection of 1 mg of SP in
325 200 µl of PBS. To induce IgE-mediated systemic anaphylaxis, anti-DNP IgE-sensitized *Mcpt5-*
326 *Cre⁺; R26Y⁺* mice received an i.p. injection of 500 µg of DNP-HSA in 200 µl PBS. Control mice
327 received an i.p. injection of 200 µl PBS. 30 to 60 min later, the fluorescence corresponding to
328 Av.SRho⁺ granule structures surrounding EYFP⁺ dermal MCs was measured using a Prairie
329 Ultima IV two-photon microscope (Spectra Physics Mai Tai HP Ti:sapphire laser, tunable from
330 690 to 1040 nm). Images were acquired in 3-D up to 30-50 µm depth, with 20x Olympus XLUM
331 Plan FI N.A. 0.95 water-immersion objective and a software zoom setting of 3 (8 bits/pixel
332 1024x1024, scaling x= 0.228 µm, y= 0.228 µm, z= 0.5 µm). Modeling and analysis of released
333 granule structures were performed using untreated image sequences, as described below in the
334 **“Granule modeling and analysis”** section.

335 *Intravital analysis of vascular permeability.*

336 The ear pinnae of C57BL/6 wild type mice were sensitized by i.d. injection of 20 ng of mouse anti-
337 DNP IgE(5) in 20 µl PBS or just received an i.d. injection of 20 µl PBS as a control. 16 hours later,
338 mice were positioned under the two-photon microscope, anesthesia was maintained by a mixture
339 of Isoflurane/O₂ and the animal's ear pinna was kept at 36°C using a heating pad system for 20
340 min. To visualize the flowing blood, mice received a retro-orbital injection of 5 mg of 70-kDa
341 dextran-FITC (#46945, Sigma Aldrich, USA) in 200 µl of PBS, as previously reported(13). To
342 induce a SP-mediated systemic response, non-sensitized *Mcpt5-Cre⁺; R26Y⁺* mice received an
343 i.p. injection of 1 mg of SP in 200 µl PBS. To induce IgE-mediated systemic anaphylaxis, anti-
344 DNP IgE-sensitized *Mcpt5-Cre⁺; R26Y⁺* mice received an i.p. injection of 500 µg of DNP-HSA in
345 200 µl PBS. Control mice received an i.p. injection of 200 µl PBS. Directly after injection of
346 stimulus or PBS, the fluorescence corresponding to dextran-FITC-label in the blood stream was

347 recorded using the same two photon microscope as described above. Images were acquired in
348 3-D up to 50-60 μm depth, with one 3-D images sequence per 1.52 min for 30 min, with 20x
349 Olympus XLUM Plan FI W. N/A95 w.d.2.0 objective and electronic zoom 1 (8 bits/pixel 512x512,
350 scaling $x= 1.37 \mu\text{m}$, $y= 1.37 \mu\text{m}$, $z= 4 \mu\text{m}$). The interstitial spaces were randomly circumscribed
351 and changes in dextran-FITC MFI were measured(13). Data were presented as fold increase from
352 basal MFI at $t=0$ on untreated image sequences using the Measurement function of Image J
353 software version Fiji.

354

355 ***Granule modeling and analysis.***

356 *Granule modeling and measurement.*

357 Untreated image sequences were processed using the Isosurface function of the Imaris Bitplane
358 X64 software version 7.6.5 (Bitplane). Based on the detection of Av.SRho fluorescence intensity
359 and employing precise measurements of the shape of the fluorescence signals, this software
360 creates an artificial solid replica in 3-D of exteriorized Av.SRho⁺ MC granule structures. The
361 minimum estimated detectable surface was defined to be of 0.25 μm of diameter, in accord with
362 the maximum resolution for 1 pixel obtained by each association
363 microscope/objective/dimensions during the fluorescence acquisition process. For the LSM 710
364 or 780/63x/1.40 Oil DIC M27 objective scaling $x= 0.264 \mu\text{m}$ and $y= 0.264 \mu\text{m}$, for the LSM
365 780/20x/0.8 WD=0.55 M27 scaling $x= 0.277 \mu\text{m}$, $y= 0.277 \mu\text{m}$ and for the Prairie Ultima 4/20x
366 Olympus XLUM Plan FI W. N/A95 w.d.2.0 objective scaling $x= 0.228 \mu\text{m}$, $y= 0.228 \mu\text{m}$. For each
367 single cell inspected, individual modeled secretory granules were analyzed for their modeled
368 volume and sphericity index. The same software settings were applied for all untreated images,
369 to fairly analyze and compare each of the experimental conditions.

370 *Virtual isolation of released granule.*

371 In some experiments, we isolated and analyzed individual released structures, separately from
372 the granule content that was attached to the cell surface. The body of each single MC was
373 modeled based the fluorescence of Fluo-4 (for confocal microscopy) or of EYFP (for two photon
374 microscopy) using the Isosurface function of the software. Data type was converted from 8 bits to
375 32 bits float, a step required by the software to initiate any Isosurface distance calculation.
376 Av.SRho⁺ granule structures were then modeled as described above and using the Distance
377 Transformation function, Av.SRho⁺ Isosurfaces (modeled externalized granule structures) were
378 isolated from the Fluo-4/EYFP⁺ Isosurface (modeled MC body) based on their proximity.
379 Av.SRho⁺ Isosurfaces overlapping with the Fluo-4/EYFP⁺ Isosurface were systematically
380 excluded from the analysis, as they correspond to the granule structures attached to the cell
381 surface. In some experiments, isolated individual released granule structures were colored
382 automatically according to their modeled volume or sphericity index, for a better appreciation of
383 their different physical characteristics.

384

385

386

387

388

389

390

391

392

393

394

395

396

Supplemental References

- 397 1. Piliponsky, A.M., Chen, C.C., Grimbaldston, M.A., Burns-Guydish, S.M., Hardy, J.,
398 Kalesnikoff, J., Contag, C.H., Tsai, M., and Galli, S.J. 2010. Mast cell-derived TNF can
399 exacerbate mortality during severe bacterial infections in *C57BL/6-Kit^{W-sh/W-sh}* mice. *Am J*
400 *Pathol* 176:926-938.
- 401 2. Le Faouder, P., Baillif, V., Spreadbury, I., Motta, J.P., Rousset, P., Chene, G., Guigne, C.,
402 Terce, F., Vanner, S., Vergnolle, N., et al. 2013. LC-MS/MS method for rapid and
403 concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty
404 acid metabolites. *J Chromatogr B Analyt Technol Biomed Life Sci* 932:123-133.
- 405 3. Metz, M., Schafer, B., Tsai, M., Maurer, M., and Galli, S.J. Evidence that the endothelin A
406 receptor can enhance IgE-dependent anaphylaxis in mice. *J Allergy Clin Immunol*
407 128:424-426 e421.
- 408 4. Lilla, J.N., Chen, C.C., Mukai, K., BenBarak, M.J., Franco, C.B., Kalesnikoff, J., Yu, M.,
409 Tsai, M., Piliponsky, A.M., and Galli, S.J. 2011. Reduced mast cell and basophil numbers
410 and function in *Cpa3-Cre; Mcl-1^{fl/fl}* mice. *Blood* 118:6930-6938.
- 411 5. Schafer, B., Piliponsky, A.M., Oka, T., Song, C.H., Gerard, N.P., Gerard, C., Tsai, M.,
412 Kalesnikoff, J., and Galli, S.J. 2012. Mast cell anaphylatoxin receptor expression can
413 enhance IgE-dependent skin inflammation in mice. *J Allergy Clin Immunol* 131:m541-548.
- 414 6. Kunder, C.A., St John, A.L., Li, G., Leong, K.W., Berwin, B., Staats, H.F., and Abraham,
415 S.N. 2009. Mast cell-derived particles deliver peripheral signals to remote lymph nodes. *J*
416 *Exp Med* 206:2455-2467.
- 417 7. Malbec, O., Roget, K., Schiffer, C., Iannascoli, B., Dumas, A.R., Arock, M., and Daeron,
418 M. 2007. Peritoneal cell-derived mast cells: an in vitro model of mature serosal-type
419 mouse mast cells. *J Immunol* 178:6465-6475.


- 420 8. Gaudenzio, N., Espagnol, N., Mars, L.T., Liblau, R., Valitutti, S., and Espinosa, E. 2009.
421 Cell-cell cooperation at the T helper cell/mast cell immunological synapse. *Blood*
422 114:4979-4988.
- 423 9. Liu, F.T., Bohn, J.W., Ferry, E.L., Yamamoto, H., Molinaro, C.A., Sherman, L.A., Klinman,
424 N.R., and Katz, D.H. 1980. Monoclonal dinitrophenyl-specific murine IgE antibody:
425 preparation, isolation, and characterization. *J Immunol* 124:2728-2737.
- 426 10. Akahoshi, M., Song, C.H., Piliponsky, A.M., Metz, M., Guzzetta, A., Abrink, M., Schlenner,
427 S.M., Feyerabend, T.B., Rodewald, H.R., Pejler, G., et al. 2011. Mast cell chymase
428 reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal
429 polypeptide in mice. *J Clin Invest* 121:4180-4191.
- 430 11. Joulia, R., Gaudenzio, N., Rodrigues, M., Lopez, J., Blanchard, N., Valitutti, S., and
431 Espinosa, E. 2015. Mast cells form antibody-dependent degranulatory synapse for
432 dedicated secretion and defence. *Nat Commun* 6:6174.
- 433 12. Wollman, R., and Meyer, T. 2012. Coordinated oscillations in cortical actin and Ca(2+)
434 correlate with cycles of vesicle secretion. *Nat Cell Biol* 14:1261-1269.
- 435 13. Egawa, G., Nakamizo, S., Natsuaki, Y., Doi, H., Miyachi, Y., and Kabashima, K. 2013.
436 Intravital analysis of vascular permeability in mice using two-photon microscopy. *Sci Rep*
437 3:1932.

438
439
440
441
442
443
444

445

Supplemental Figures and Legends


Supplemental Figure 1



446

447 **Supplemental Figure 1. Fluorochrome-labelled avidin enables real-time detection of**
 448 **exteriorized mast cell secretory granule structures.** IgE-sensitized or non-sensitized PBCMCs
 449 were stimulated with 2 µg/ml of anti-IgE in the presence of Sulforhodamine 101-coupled avidin
 450 (Av.SRho, red). (A) Representative time-lapse sequence of a single PBCMC stimulated with anti-
 451 IgE; upper panel: Av.SRho fluorescence merged with Differential Interference Contrast (DIC),
 452 lower panel: Av.SRho enrichment (pseudocolor scale). (B, C) 30 min after degranulation, cells
 453 were fixed then stained with an Alexa488-coupled anti-IgE (green, to detect surface IgE), cells
 454 were then permeabilized and stained for tryptase content (blue). (B) Representative confocal
 455 microscopy pictures of a single degranulated PBCMC, Av.SRho, IgE and tryptase fluorescence
 456 are merged (upper panel), Av.SRho and IgE fluorescence are merged (mid panel), Av.SRho and
 457 tryptase fluorescence are merged (lower panel). (C) Fluorescence colocalization analysis for each
 458 of the pictures depicted in (B) along the white dotted line. Bar = 5µm.


Supplemental Figure 2



459


460 **Supplemental Figure 2. Substance P- or anti-IgE-mediated mast cell degranulation**
461 **dynamics does not depend on the concentration of stimulus.** IgE-sensitized or non-
462 sensitized PBCMCs were stimulated with 0.5 or 2 µg/ml of anti-IgE (blue) or with 2.5 or 10 µM of
463 SP (pink), respectively, in the presence of Alexa488-coupled avidin (Av.A488). Fluorescence
464 signal was measured using time-lapse flow cytometry. (A, B) Representative curves of Av.488
465 fluorescence signal monitoring in PBCMCs stimulated with (A) anti-IgE or (B) SP. Data are
466 representative of the 3 independent experiments performed, each with PBCMCs from a different
467 donor, each of which gave similar results.

Supplemental Figure 3




469 **Supplemental Figure 3. In human mast cells, SP-induced rapid degranulation dynamics is**
470 **mediated via MRGPRX2 activation.** PBCMCs were transfected with shRNA control (shCTRL)
471 or shRNA directed against *MRGPRX2* (shMrgX2). Each shRNA also encoded GFP to permit
472 identification of the transfected cells. IgE-sensitized or non-sensitized previously transfected
473 PBCMCs were stimulated or not with anti-IgE or SP, respectively, in the presence of Av.SRho.
474 Av.SRho fluorescence was measured in single GFP⁺ cells using time-lapse confocal microscopy
475 in a controlled atmosphere (37°C and 5% CO₂). **(A)** Representative confocal microscopy pictures
476 of MRGPRX2 (red) and GFP (green) staining in PBCMCs. Green arrows indicate shRNA-
477 transfected PBCMCs expressing GFP. **(B, C)** Representative time-lapse sequence of Av.SRho
478 enrichment (color scale) in a single **(B)** shCTRL-transfected PBCMC or **(C)** shMrgX2-transfected
479 PBCMC stimulated with 10 μM of SP. Numbers = minutes (min). **(D, E)** Single cell analysis of
480 Av.SRho MFI over time in individual **(D)** shCTRL-transfected PBCMCs or **(E)** shMrgX2-
481 transfected PBCMC stimulated with 10 μM of SP or medium. **(F)** Mean curves of Av.SRho MFI in
482 shCTRL- (pink squares) or shMrgX2- (pink circles) transfected PBCMCs stimulated with 10 μM
483 of SP or medium (open squares). **(G, H)** Representative time-lapse sequence of Av.SRho
484 enrichment (color scale) in a single **(G)** shCTRL-transfected PBCMC or **(H)** shMrgX2-transfected
485 PBCMC stimulated with 2 μg/ml of anti-IgE. Numbers = minutes (min). **(I, J)** Single cell analysis
486 of Av.SRho MFI in a single IgE-sensitized **(I)** shCTRL-transfected PBCMC or **(J)** shMrgX2-
487 transfected PBCMC stimulated with 2 μg/ml of anti-IgE or medium. **(K)** Mean curves of Av.SRho
488 MFI in IgE-sensitized shCTRL- (blue squares) or shMrgX2- (blue circles) transfected PBCMCs
489 stimulated with anti-IgE or medium (open squares). Bars = 5 μm. Two-way ANOVA, ****P<.0001.
490 Data are pooled from the 3 independent experiments performed with PBCMCs from one donor
491 (25 single PBCMCs analyzed per condition), each of which gave similar results.

Supplemental Figure 4



493 **Supplemental Figure 4. Human mast cell activation by different cationic ligands results in**
494 **similar degranulation dynamics.** Non-sensitized PBCMCs were stimulated with 10 μ M of SP
495 (pink), 1 μ g/ml of compound 48/80 (brown), 10 μ M of Icatibant (orange) or 10 μ M of Cetorelix
496 (yellow) in the presence of Av.A488 (for flow cytometry) or Av.SRho (for confocal microscopy).
497 (A) Representative flow cytometry dot plots of Av.A488 fluorescence in PBCMCs 30 min after
498 addition of cationic stimuli or medium. (B) Av.A488 fluorescence intensity, (C) propidium iodide
499 (PI) staining, and (D) percentage of β -hexosaminidase release in PBCMCs 30 min after addition
500 of cationic stimuli or medium. Mean + SEM; data are pooled from the 3 independent experiments
501 performed with PBCMCs from 3 different donors, each of which gave similar results. (E)
502 Representative curves of Av.488 fluorescence signal monitoring in PBCMCs upon addition of
503 cationic stimuli or medium. (F) Representative time-lapse sequence of Av.SRho enrichment (color
504 scale) in a single PBCMC stimulated with 10 μ M of SP. (G) Analysis of Av.SRho MFI in the
505 PBCMC depicted in (F). (H-M) Same experiments as in (F, G) but with, respectively, (H, I) 1 μ g/ml
506 of compound 48/80, (J, K) 10 μ M of Icatibant, or (L, M) and 10 μ M of Cetorelix. Bars = 5 μ m.
507 Data are representative of 10 single cells analyzed for each condition of stimulation with PBCMCs
508 from 3 different donors, with replicate experiments giving similar results.


Supplemental Figure 5



510 **Supplemental Figure 5. Human mast cell activation by C3a, C5a or ET-1 induces a spatio-**
511 **temporal signature of degranulation distinct from that induced following FcγR-**
512 **crosslinking.** Non-sensitized PBCMCs were stimulated with 2 μg/ml of C5a (purple), 2 μg/ml of
513 C3a (cyan), 1 μM of ET-1 (gold) or 1 μg/ml of mouse IgG immune complexes (green), in the
514 presence of Av.SRho. Av.SRho fluorescence was measured at the single cell level using time-
515 lapse confocal microscopy in a controlled atmosphere (37°C and 5% CO₂). (A) Percentage of
516 Av.SRho⁺ cells per field as compared to cells stimulated with anti-IgE (blue) or SP (pink). (B)
517 Av.SRho MFI per single cell as compared to anti-IgE (blue) or SP (pink). (C, E, G, I)
518 Representative time-lapse sequence of Av.SRho enrichment (color scale) in single PBCMCs
519 stimulated with (C) 2 μg/ml of C5a, (E) 2 μg/ml of C3a, (G) 1 μM ET-1, and (I) 1 μg/ml of mouse
520 IgG immune complexes. (D, F, H, J) Curves of single cell analyzes of Av.SRho MFI in PBCMCs
521 stimulated with (D) 2 μg/ml of C5a, (F) 2 μg/ml of C3a, (H) 1 μM of ET-1, and (J) 1 μg/ml of mouse
522 IgG immune complexes (in each graph, the same data for PBCMCs stimulated with medium alone
523 are presented in grey color for reference). (K) Mean ± SEM of pooled experiments described in
524 D, F, H, J. Bars in C, E, G, I = 5 μm. Data in D, F, H, J, K are from 4 independent experiments
525 performed with cells from 1 donor (between 30 and 40 single PBCMCs analyzed per condition),
526 with replicate experiments giving similar results.

530 Non-sensitized Fluo-4-loaded PBCMCs were stimulated with 2 $\mu\text{g/ml}$ of C5a (purple), 2 $\mu\text{g/ml}$ of
531 C3a (cyan), 1 μM of ET-1 (gold) or 1 $\mu\text{g/ml}$ of mouse IgG immune complexes (green), in the
532 presence of Av.SRho. Fluo-4 (green, $[\text{Ca}^{2+}]_i$) and Av.SRho (red) fluorescence was measured, at
533 the single cell level, using time-lapse confocal microscopy in a controlled atmosphere (37°C and
534 5% CO_2). (A, C, E, G) Representative time-lapse sequence of a single PBCMC activated with 2
535 $\mu\text{g/ml}$ of C5a (A), 2 $\mu\text{g/ml}$ of C3a (C), 1 μM of ET-1 (E) or 1 $\mu\text{g/ml}$ of mouse IgG immune complexes
536 (G). Bars = 5 μm , white insets show a budding granule structure at higher magnification, arrows
537 indicate first budding granule structures; note that the time sequences of the pictures shown are
538 varied according to the type of stimulation that was assessed. (B, D, F, H) Mean curves of Fluo-
539 4 and Av.SRho MFI following stimulation with 2 $\mu\text{g/ml}$ of C5a (B), 2 $\mu\text{g/ml}$ of C3a (D), 1 μM of ET-
540 1 (F) or 1 $\mu\text{g/ml}$ of mouse IgG immune complexes (H); dotted lines and arrows indicate the lag
541 time (ΔT) measured between the beginning of the increase in $[\text{Ca}^{2+}]_i$ and the detection of the first
542 budding granule structures. (I) Mean ΔT measured following each type of stimulation. Mean +
543 SEM; two-tailed, unpaired t test, *** $P < .001$, **** $P < .0001$. Data are from 3 independent
544 experiments performed with PBCMCs from 2 donors (at least 30 single PBCMCs analyzed per
545 condition), each of which gave similar results.

Supplemental Figure 7



546


547 **Supplemental Figure 7. Mouse peritoneal cell-derived mast cells (PCMCs) activated *via* IgE**

548 **and specific antigen exhibit an “anti-IgE-like” degranulation pattern. Anti-DNP IgE-**

549 sensitized PCMCs were stimulated with 10 ng/ml DNP-HSA or vehicle as a control. **(A)**
550 Percentage of β -hexosaminidase release 60 minutes after stimulation. **(B)** Representative time-
551 lapse sequence of a single stimulated PCMC in the presence of Av.SRho (red), fluorescence
552 was measured, at the single cell level, using time-lapse confocal microscopy in a controlled
553 atmosphere (37°C and 5% CO₂). **(C)** Mean curves of pooled single cell analyzes of Av.SRho MFI.
554 **(D-G)** Anti-DNP IgE-sensitized dextran-FITC-loaded PCMCs were stimulated with 10 ng/ml DNP-
555 HSA or vehicle (as a control) in the presence of Av.SRho. Dextran-FITC and Av.SRho
556 fluorescence were measured simultaneously, at the single cell level, using time-lapse confocal
557 microscopy in a controlled atmosphere (37°C and 5% CO₂). **(D)** Representative time-lapse
558 sequence of Av.SRho (upper panel, red) and dextran-FITC enrichment (lower panel, pseudo-
559 color scale) in a single PCMC stimulated with vehicle (control) **(D)** or DNP-HSA **(E)**. **(F)** Mean
560 curves of pooled single cell analyzes of dextran-FITC MFI in PCMCs stimulated with vehicle
561 (control, black) or DNP-HSA (blue). **(G)** Average of dextran-FITC MFI between t=0 and t=5 min.
562 Mean \pm SEM; two-tailed, unpaired *t* test, ***P<.001; data are from 4 independent experiments (at
563 least 40 single PCMCs analyzed per condition), each of which gave similar results.


564

Supplemental Figure 8



566 **Supplemental Figure 8. Human mast cell activation by antibody-independent signals does**
567 **not enhance intracellular homotypic (i.e., granule-granule) fusion events.** PBCMCs were
568 incubated with 1 mg/ml of dextran-FITC for 48 h. PBCMCs not sensitized with IgE were stimulated
569 with 2 μ g/ml of C5a (purple) or medium alone (black), in the presence of Av.SRho. Dextran-FITC
570 and Av.SRho fluorescence were measured simultaneously, at the single cell level, using time-
571 lapse confocal microscopy in a controlled atmosphere (37°C and 5% CO₂). (A) Representative
572 time-lapse sequence of Av.SRho (upper panel, red) and dextran-FITC enrichment (lower panel,
573 pseudo-color scale) in a single PBCMC stimulated with 2 μ g/ml of C5a. (B) Mean curve of pooled
574 single cell analyzes of dextran-FITC MFI in PBCMCs stimulated with 2 μ g/ml of C5a. (C-H) Same
575 experiments as the one depicted in (A, B) but in PBCMCs stimulated respectively with (C, D) 1
576 μ M of C3a (cyan), (E, F) 2 μ g/ml of ET-1 (gold) or (G, H) 1 μ g/ml of mouse IgG immune complexes
577 (green, white arrows indicate increases in dextran-FITC fluorescence) or medium control (in each
578 graph in B, D, F, H, the same data for PBCMCs stimulated with medium alone are presented in
579 a grey color for reference). Bars = 5 μ m. The same PBCMCs stimulated with medium alone are
580 used as control in Figure 3 and in Supplemental Figure 8. (I) Average of dextran-FITC MFI
581 between t=0 and t=5 min. Mean \pm SEM; two-tailed, unpaired *t* test, *P<.05, **P<.01, ****P<.0001;
582 data are from 4 independent experiments performed with PBCMCs from 2 donors (between 30
583 and 35 single PBCMCs analyzed per condition), each of which gave similar results.

Supplemental Figure 9



584

585 **Supplemental Figure 9. TEM analysis of mast cell granule structures exteriorized during**


586 **Substance P- or anti-IgE-mediated mast cell degranulation.** IgE-sensitized or non-sensitized

587 PBCMCs were incubated in the presence of anti-IgE (blue) or SP (pink) respectively, or with RPMI

588 medium alone (No stimulation, black), and analyzed by TEM 3 min after the beginning of

589 stimulation. **(A)** Representative TEM micrographs of individual PBCMCs; **red lines** indicate
590 structures (“channels”) formed by the fusion of granule membranes with each other and the
591 plasma membrane, **green** asterisks indicate examples of exteriorized granule structures that are
592 apparently separated from cell, **yellow** asterisks indicate examples of granule structures that
593 appear to be within channels in continuity with the cell surface, and white asterisks (in cells
594 incubated solely with vehicle) indicate some of the intracellular granule structures. **(B)**
595 Representative high magnification TEM micrograph of a PBCMC stimulated with anti-IgE; **green**
596 lines indicate examples of the granule structures separated from cell that are analyzed in **panel**
597 **C**, **yellow** lines indicate examples of granule structures that appear to be within channels or
598 invaginations in continuity with the cell surface (such granule structures are not included in the
599 data shown in **panel C**). Insets show higher magnifications of the areas indicated with black dotted
600 squares. **(C)** Mean calculated area (in μm^2) of more than ~ 700 individual granule structures
601 visually separated from cell. Left panel: each dot represents one individual granule structure
602 analyzed and right panel: mean \pm SEM of the data shown in the left panel. Two-tailed, unpaired t
603 test, ****P < .0001. Data are from TEM micrograph of ~ 60 individual PBCMCs per condition from
604 2 individual experiments performed with 2 donors, each of which gave similar results. Bar = 2 μm .

Supplemental Figure 10



605

606 **Supplementary Figure 10. Assessment of the specificity of the anti-STX4, anti-SNAP-23**


607 **and anti-STX-3 antibodies used for immunoprecipitation.** Detection of STX-4 (A), SNAP-23

608 (B) or STX-3 (C) in lysates of unstimulated PBMCs lysates or in specimens of recombinant human

609 proteins. Data are from 2 independent experiments, each of them performed with PBMCs from

610 a different single donor, each of which gave similar results.

Supplemental Figure 11



611

612 **Supplemental Figure 11. Detection and modeling of exteriorized mast cell granule**

613 **structures using the Av.SRho technique and Surface functions of Imaris. (A)**

614 Superimposition on the same image of all the Av.SRho⁺ exteriorized granule structures (which

615 could be individual granules or aggregates of individual granules) detected using confocal laser-

616 scanning microscopy during the first 3 minutes after the beginning of degranulation induced in

617 human PBCMCs stimulated with anti-IgE (conditions as described in Figure 2). This

618 representative picture shows how many Av.SRho⁺ granule structures are detected in one focal

619 plane during 3 minutes of degranulation. **(B)** Each individual Av.SRho⁺ granule structure is

620 modeled and converted into a 3-D object; the software takes into consideration the precise shape


621 and intensity of the fluorescent signal. This representative picture shows that most (if not 100%)

622 of the structures with a detectable fluorescent signal are converted into 3-D objects and can be

623 directly analyzed for their modeled volume using a pseudo color intensity scale. **(C)** Classification

624 of all the created 3-D objects according to their modeled volumes. This picture shows that, in
625 general, the larger of the modeled Av.SRho⁺ structures have a higher proportion of structures with
626 more irregular shapes.


Supplemental Figure 12



627
628 **Supplemental Figure 12. I.d injection of 1 nmol of SP or 5 ng of DNP-HSA induces a similar**
629 **extent of dermal mast cell degranulation.** Mice were sensitized by i.d. injection of 20 ng anti-

630 DNP-HSA IgE into the left ear pinna and vehicle alone (as a control) was injected i.d. into the right
631 ear pinna. 16 h later, the right ear pinna was injected i.d. with 1 nmol of SP (pink) and the left with
632 5 ng of DNP-HSA (blue). In control experiments, both ear pinnae were injected i.d. with vehicle
633 (black). **(A)** Representative photographs of MC degranulation in the ear pinnae of Mcpt5-EYFP
634 mice 30-60 min after injection of vehicle (upper panels), DNP-HSA (middle panels) or SP (lower
635 panels). From left to right: Av.SRho (red) and EYFP (green) fluorescence merged; Av.SRho (red);
636 3 examples of degranulated MCs (left to right: Av.SRho/EYFP/Av.SRho/Av.SRho enrichment).
637 Bars = 20 μ m. **(B)** Quantification of the percentage of Av.SRho⁺ (red) vs Av.SRho⁻ (white) EYFP⁺
638 tissue MCs. **(C)** Single cell analysis of Av.SRho MFI (each dot = value for a single MC). **(D)**
639 Toluidine blue analysis of MC degranulation 60 min after injection of vehicle, DNP-HSA or SP;
640 upper panel: representative picture of ear pinnae sections; lower panel: percentage and intensity
641 of MC degranulation, as determined by classification in three categories, not degranulated (None,
642 grey), moderately degranulated (Mod, darker grey) and extensively degranulated (Ext, black).
643 n=total number of mice per condition.

Supplemental Figure 13



644

645 **Supplemental Figure 13. Mast cell activation *in vivo* by different cationic compounds**


646 **results in similar Evan's blue extravasation dynamics.** Ear pinnae of naïve mice were injected

647 i.d. with 1 nmol of SP (pink), 400 ng of compound 48/80 (brown), 1 nmol of Icatibant (orange), 1


648 nmol of Cetrorelix (yellow), or vehicle alone (black). (A) Evan's blue extravasation in the ear
649 pinnae of C57BL/6 wild type mice. Left panels: representative photographs of ears, right panels:
650 measurements of Evan's blue extravasation per ear (OD 650 nm), at 15, 30 or 60 min after i.d.
651 injection. Mean \pm SEM; two-way ANOVA, ***P<.001. Data are pooled from the 3 independent
652 experiments performed, each of which gave similar results. (B) Evan's blue extravasation in the
653 ear pinnae of MC-deficient C57BL/6-Kit^{W-sh/W-sh} mice versus C57BL/6 wild-type mice. Left panels:
654 representative photographs of ears and right panels: measurements of Evan's blue extravasation
655 per ear (OD 650 nm), 60 min after i.d. injection. Mean \pm SEM; two-tailed, unpaired *t* test, *P<.05
656 **P<.01 ***P<.001. Data are pooled from 3 independent experiments performed, each of which
657 gave similar results. n=total number of mice per condition.

Supplemental Figure 14


A




B



C



D



659 **Supplemental Figure 14. Different effects on plasma extravasation dynamics and body**
660 **temperature during MRGPRB2- vs. FcεRI-mediated responses in mice. (A)** *C57BL/6* wild
661 type mice were sensitized or not with i.d. injection into the ear pinna of 20 ng of mouse anti-DNP-
662 HSA IgE or vehicle as a control. 16 h later, we retro-orbitally injected 250 μg of 70-kDa dextran-
663 FITC and the anesthetized mouse was positioned under the two-photon microscope. Non-
664 sensitized mice were injected i.p. with 1 mg of SP. Anti-DNP IgE-sensitized mice were injected
665 i.p. with 500 μg of DNP-HSA. In control experiments, sensitized mice were injected i.p. with
666 vehicle alone. Image sequences were acquired in 3-D at a rate of one picture per min over 30
667 min. **(B)** Representative 3-D time-lapse sequences of dextran-FITC fluorescence. Bars = 50 μm.
668 **(C)** Fold changes in dextran-FITC MFI in the interstitial space following injection of SP (pink),
669 DNP-HSA (blue) or vehicle (black). **(D)** *C57BL/6-Kit^{+/+}* or *C57BL/6-Kit^{W-sh/W-sh}* mice were sensitized
670 or not with an i.p. injection of 10 μg of mouse anti-DNP-HSA IgE. 16 h later, non-sensitized or
671 sensitized animals were injected i.p. with 1 mg of SP (pink) or 500 μg of DNP-HSA (blue),
672 respectively, or with vehicle alone (black). Mouse body temperature (°C) was measured over 120
673 min. **(C-D)** Mean ± SEM; two-way ANOVA, **P < .01, ***P < .001, ****P < .0001. Data were pooled
674 from the 3 individual experiments performed for each condition of stimulation, each of the replicate
675 experiments giving similar results. n=total number of mice per condition.

676

677 **Supplemental Video 1. Human mast cell intracellular calcium flux and degranulation**
678 **dynamics upon stimulation with anti-IgE or SP.** IgE-sensitized or non-sensitized PBCMCs
679 were loaded with Fluo-4 and stimulated with anti-IgE antibodies or SP in the presence of Av.SRho.
680 Fluo-4 (green, [Ca²⁺]_i) and Av.SRho (red) fluorescence signals were monitored, at the single cell
681 level, using time-lapse confocal microscopy in a controlled atmosphere (37°C and 5% CO₂).

682

683 **Supplemental Video 2. Monitoring of dextran-FITC fluorescence dequenching in human**
684 **mast cells stimulated with anti-IgE or SP.** PBCMCs were incubated with 1 mg/ml of dextran-
685 FITC for 48 h. IgE-sensitized or non-sensitized PBCMCs were stimulated with 2 µg/ml of anti-IgE
686 or 10 µM of SP, respectively, or with vehicle alone, in the presence of Av.SRho. Dextran-FITC
687 (pseudo-color scale) and Av.SRho (red) fluorescence signals were monitored, at the single cell
688 level, using time-lapse confocal microscopy in a controlled atmosphere (37°C and 5% CO₂).

689
690 **Supplemental Video 3. Monitoring of dextran-FITC fluorescence dequenching in human**
691 **mast cells stimulated with C5a, C3a, ET-1 or IgG immune complexes.** PBCMCs were
692 incubated with 1 mg/ml of dextran-FITC for 48 h. Non-sensitized PBCMCs were stimulated with
693 1 µg/ml of C5a (purple), 1 µg/ml of C3a (cyan), 1 µM of ET-1 (gold), 1 µg/ml of IgG immune
694 complexes (green), or with vehicle alone (white), in the presence of Av.SRho. Dextran-FITC
695 (pseudo-color scale) and Av.SRho (red) fluorescence were monitored, at the single cell level,
696 using time-lapse confocal microscopy in a controlled atmosphere (37°C and 5% CO₂).

697
698 **Supplemental Video 4. Effects of treatment with an IKKβ selective inhibitor on human mast**
699 **cell intracellular calcium flux and degranulation dynamics.** IgE-sensitized or non-sensitized
700 PBCMCs were pretreated during 60 min with 100 µM of BMS-345541 or DMSO as a control,
701 loaded with Fluo-4 and stimulated with anti-IgE antibodies or SP in the presence of Av.SRho.
702 Fluo-4 (green, [Ca₂⁺]_i) and Av.SRho (red) fluorescence signals were monitored, at the single cell
703 level, using time-lapse confocal microscopy in a controlled atmosphere (37°C and 5% CO₂).

704
705 **Supplemental Video 5. Effects of treatment with an IKKβ selective inhibitor on dextran-**
706 **FITC fluorescence dequenching in human mast cells stimulated with anti-IgE.** PBCMCs
707 were incubated with 1 mg/ml of dextran-FITC for 48 h. IgE-sensitized or non-sensitized PBCMCs

708 were pretreated during 60 min with 100 μ M of BMS-345541 or DMSO as a control and stimulated
709 with 2 μ g/ml of anti-IgE in the presence of Av.SRho. Dextran-FITC (pseudo-color scale) and
710 Av.SRho (red) fluorescence signals were monitored, at the single cell level, using time-lapse
711 confocal microscopy in a controlled atmosphere (37°C and 5% CO₂).

712

713 **Supplemental Video 6. Modeling of budding granule structures in human mast cells**
714 **stimulated with anti-IgE or SP.** IgE-sensitized or non-sensitized PBCMCs were stimulated with
715 2 μ g/ml of anti-IgE or 10 μ M of SP, respectively, in the presence of Av.SRho (red). Fluorescence
716 was acquired using a confocal microscope and individual budding granule structures (i.e., those
717 undergoing exteriorization and therefore available to bind Av.SRho) were modeled using the
718 Isosurface function of Imaris software. Videos of MCs are started when the first budding granule
719 structures were detected in that cell.

720

721 **Supplemental Video 7. Modeling of externalized granule structures in human mast cells**
722 **stimulated with anti-IgE or SP.** IgE-sensitized or non-sensitized PBCMCs were loaded with
723 Fluo-4 (green), embedded in a surrogate extracellular matrix gel and stimulated with 2 μ g/ml of
724 anti-IgE or 10 μ M of SP, respectively, or with vehicle alone, in the presence of Av.SRho (red). 30
725 min later, 3-D pictures were acquired using a confocal microscope and the fluorescence of
726 granule matrices released beyond the perimeter of the MCs was modeled using the Isosurface
727 function of Imaris software. In the video, the transition from the actual images obtained to modeled
728 fluorescence occurs roughly at the mid-point of the video.

729

730 **Supplemental Video 8. Analysis of mast cell granule structures exteriorized during IgE-**
731 **dependent or IgE-independent reactions *in vivo*.** *Mcpt5-Cre⁺; R26Y⁺* mice were sensitized or
732 not by i.d. injection into the ear pinna of 20 ng of mouse anti-2, 4-dinitrophenyl (DNP) IgE. 16 h

733 later, 8 μ g of Av.SRho was injected i.d. into the same ear pinna. Non-sensitized mice were injected
734 i.p. with 1 mg of SP. Anti-DNP IgE-sensitized mice were injected i.p. with 500 μ g of DNP-HSA. In
735 control experiments, IgE-sensitized mice were injected i.p. with vehicle. 30 minute later, 3-D
736 pictures were acquired using a two-photon microscope and fluorescence corresponding to EYFP⁺
737 MCs (green) and Av.SRho (red) (identifying budding or exteriorized granule structures) was
738 modeled using the Isosurface function of Imaris software. In the video, the transition from actual
739 obtained images to modeled fluorescence occurs roughly at the mid-point of the video.


740

741 **Supplemental Video 9. Plasma extravasation dynamics during IgE-dependent or IgE-**
742 **independent reactions *in vivo*.** C57BL/6 wild type mice were sensitized or not by i.d. injection
743 into the ear pinna of 20 ng of mouse anti-DNP IgE or vehicle. 16 h later, we retro-orbitally injected
744 250 μ g of 70-kDa dextran-FITC (pseudo-color scale) and the anesthetized mice were positioned
745 under the two-photon microscope. Non-sensitized mice were injected i.p. with 1 mg of SP and
746 anti-DNP IgE-sensitized mice were injected i.p. with 500 μ g of DNP-HSA. In control experiments,
747 IgE-sensitized mice were injected i.p. with vehicle. Image sequences were acquired in 3-D at a
748 rate of one picture per min over 30 min using a two-photon microscope.

Full unedited gel for Figure 3H

Phospho AKT

Phospho AKT



Full unedited gel for Figure 3H Phospho IKKb



Phospho IKK α (S176)/ β (S177)

Full unedited gel for Figure 3H Phospho PKC

Phospho PKC




Full unedited gel for Figure 3H total Actin




Full unedited gel for Figure 3I coIP STX4

coIP STX-4 



Full unedited gel for Figure 3I IP SNAP23


IP SNAP-23



Full unedited gel for Figure 3J coIP STX3

coIP STX-3 

 STX3



Full unedited gel for Figure 3J IP MUNC18.2


IP MUNC18.2




Full unedited gel for Figure 4E Phospho IKKb




Full unedited gel for Figure 4F colP STX4


colP STX-4



Full unedited gel for Figure 4F IP SNAP23



Full unedited gel for Supplemental Figure 10 SNAP23



Full unedited gel for
Supplemental Figure 10 STX3

hw p8mcs

rec Syn 3

rec syn 23

rec syn 4

Full unedited gel for Supplemental Figure 10
STX4

3

STX4 1/5
STX4 1/5
STX4 1/5

STX4 1/5
STX4 1/5

STX4 1/5
STX4 1/5